4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Biogen's Leqembi generated $184 million in global Q2 2026 sales, up 15% year over year, while Biogen recorded $63.7 million in Alzheimer’s collaboration revenue, up 16%; the FDA-approved subcutaneous Leqembi Iqlik could support broader uptake. The article highlights pipeline catalysts across Alnylam, Prothena and Acumen, including Acumen’s late-2026 phase II sabirnetug readout in 542 early Alzheimer’s patients and Prothena’s fully enrolled ~310-patient phase II moponetug study, due to complete in H1 2027. Clinical risk remains material, as Biogen’s diranersen missed its phase II primary endpoint despite favorable biomarker signals and planned phase III advancement.

Analysis

This is not a sector-level demand catalyst; it reinforces that Alzheimer’s monetization remains constrained by diagnosis, infusion capacity, MRI monitoring, and payer friction rather than by drug availability alone. The highest-quality near-term beneficiary is LLY, whose scale, neurology sales force, and existing payer leverage should allow it to convert expanded treatment adoption more efficiently than BIIB/Eisai. BIIB’s economics are notably less attractive: its share of the franchise is reported after collaboration cost sharing, so headline prescription growth will not translate one-for-one into Biogen EPS.

The key competitive variable over the next 1-3 months is whether home-administered treatment reduces abandonment and shifts the treatment setting from hospital infusion centers toward specialty pharmacy. If that occurs, LLY faces a more meaningful competitive threat to Kisunla than the current sales run-rate implies, while service providers exposed to infusion utilization could see modest volume pressure. But market expectations should remain anchored to real-world persistence, ARIA monitoring burden, and diagnostic throughput; convenience alone does not eliminate these bottlenecks.

ABOS is the cleanest event vehicle into its late-2026 readout, but it is a binary clinical-risk position, not a fundamental rerating story. Its oligomer thesis must show cognitive efficacy and a materially differentiated safety profile; biomarker change without a persuasive clinical signal would likely impair both ABOS and the broader premium assigned to next-generation amyloid approaches. PRTA has a longer-duration option on tau, but the partnered structure limits upside capture, while ALNY’s neuroscience assets are too early to move a valuation driven principally by its established RNAi platform.

Contrarian view: investor attention may overvalue mechanistic novelty in tau and RNAi programs while underweighting the commercial moat of large-scale patient identification. Watch memory-clinic referral volumes, CMS coverage implementation, treatment discontinuation, and quarterly net-price trends. A slowdown in these indicators would matter more for BIIB and LLY over the next 6-18 months than incremental early-stage biomarker disclosures.

Key Decisions for Investors

• Maintain a relative long LLY / short BIIB position over 3-6 months: LLY has superior commercialization leverage and can absorb access costs; BIIB is more exposed to slower-than-expected net revenue conversion. Reassess if BIIB’s Alzheimer’s collaboration revenue growth materially outpaces LLY’s Kisunla trajectory for two consecutive quarters.
• Do not chase ABOS on awareness-driven flow. Establish only a small, defined-risk catalyst position 3-6 months before late-2026 data using call spreads, contingent on cash runway extending beyond the readout and no evidence of worsening trial attrition; size for a potential 50%+ drawdown on negative efficacy or ARIA data.
• Treat PRTA as a watchlist, not a core Alzheimer’s exposure, through the first-half 2027 tau readout. The risk/reward improves only if its enterprise value remains near cash-adjusted levels and Bristol Myers provides evidence of continued strategic commitment to moponetug.
• Use ALNY weakness rather than Alzheimer’s headlines to add exposure over 6-18 months; its AD programs are optionality, not a near-term earnings driver. Falsify the incremental neuroscience thesis if phase I safety or CNS target-engagement data fail to support repeat dosing.
• Set an operational adoption dashboard for BIIB and LLY: quarterly treated-patient growth, discontinuation rates, MRI capacity, and realized net pricing. A sustained improvement in these measures is the trigger to increase exposure to the Alzheimer’s commercial franchise rather than preclinical competitors.